Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo

(2010) Vandana Kalia et al.   IMMUNITY

An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells

(2010) J. F. Martin et al.   JOURNAL OF IMMUNOLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource

(2009) Calliope A Dendrou et al.   NATURE GENETICS

Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells

(2008) Philip L. De Jager et al.   BRAIN

NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis

(2008) Eliana A. G. Reis et al.   RHEUMATOLOGY INTERNATIONAL